Cytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer.
PRINCETON, New JerseyCytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer. CYT-500 targets prostate-specific membrane antigen (PSMA), which is abundantly expressed on the surface of prostate cancer cells. The agent incorporates the same monoclonal antibody used in Cytogen's ProstaScint (capromab pendetide) molecular imaging agent but is linked to a therapeutic payload.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.